finance
Eight Mainland Chinese Companies Pass Hong Kong Stock Listing Hearings in April
Eight companies based in mainland China, including five biotech firms, cleared listing hearings on the Hong Kong stock market this month. The group features an AI-driven drug discovery firm and others in advanced technology sectors. This development aligns with regulatory pushes from Beijing to encourage Hong Kong listings.
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eight mainland China-based companies passed listing hearings on the Hong Kong stock market in April 2026, according to the South China Morning Post. Five of these companies are biotech firms. The approved entities include an AI-driven drug discovery firm, a driverless technology developer, and a maker of industrial robots.
The influx occurs as the China Securities Regulatory Commission (CSRC) has been pushing private firms to list in Hong Kong. The CSRC has required companies that established red-chip structures before 2023 to reincorporate on the mainland and pursue Hong Kong share offerings.
These structures involve offshore holding vehicles typically set up in places like the Cayman Islands to control China-based businesses.
Among the applicants, Metis TechBio applied for listing under Chapter 18C of the Hong Kong exchange, a regime for pre-profit specialist technology firms. Metis TechBio's latest filing with the Hong Kong exchange occurred on Sunday. Jefferies, Deutsche Bank, and Citic Securities are joint sponsors of Metis TechBio's listing deal.
Metis TechBio was founded in 2020 in Hangzhou, Zhejiang province, eastern China. The company operates in China and the United States. It uses three proprietary AI platforms to design and optimise drug delivery systems, which refer to how medicines are packaged and processed by the body.
48 million yuan in 2024. 2 million yuan in 2024. Its leading drug candidate, MTS-004, is an orally dissolving tablet for pseudobulbar affect and has completed phase three clinical trials.
